Employing Macrophage-Derived Microvesicle for Kidney-Targeted Delivery of Dexamethasone: An Efficient Therapeutic Strategy against Renal Inflammation and Fibrosis: Erratum

Tang, Tao-Tao; Lv, Lin‐Li; Wang, Bin; Cao, Jun; Ye, Feng; Li, Zuo‐Lin; Wu, Min; Wang, Fengmei; Wen, Yi; Zhou, Le-Ting; Ni, Haifeng; Chen, Pingsheng; Gu, Ning; Crowley, Steven D.; Liu, Bi‐Cheng

doi:10.7150/thno.78981

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EVs can naturally be secreted by diverse cell types, such as macrophages and cancer cells, and are known for their non-cytotoxicity, non-immunogenicity, and excellent biocompatibility ( 41 ). In addition, the presence of consistent adhesion molecules on the EV surface facilitates preferential binding to host cells and helps them evade phagocytosis by endothelial reticulocytes ( 42 , 43 ). EVs also play a crucial role in intercellular communication by transferring their cargo to various cells, thereby promoting cell transcription and proliferation ( 44 ).…”

Section: Drugs Delivery Systemmentioning

confidence: 99%

Natural biomimetic nano-system for drug delivery in the treatment of rheumatoid arthritis: a literature review of the last 5 years

Li,

Zhuang

2024

Front. Med.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized primarily by synovitis, leading to the destruction of articular cartilage and bone and ultimately resulting in joint deformity, loss of function, and a significant impact on patients’ quality of life. Currently, a combination of anti-rheumatic drugs, hormonal drugs, and biologics is used to mitigate disease progression. However, conventional drug therapy has limited bioavailability, and long-term use often leads to drug resistance and toxic side effects. Therefore, exploring new therapeutic approaches for RA is of great clinical importance. Nanodrug delivery systems offer promising solutions to overcome the limitations of conventional drugs. Among them, liposomes, the first nanodrug delivery system to be approved for clinical application and still widely studied, demonstrate the ability to enhance therapeutic efficacy with fewer adverse effects through passive or active targeting mechanisms. In this review, we provide a review of the research progress on the targeting mechanisms of various natural biomimetic nano-delivery systems in RA therapy. Additionally, we predict the development trends and application prospects of these systems, offering new directions for precision treatment of RA.

show abstract